Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers

Thrombosis and Haemostasis

Volumn 93, Issue 4, 2005, Pages 794-795

  Hinder, Markus ^a   Paccaly, Anne ^b   Frick, Annke ^a   Shukla, Umesh ^b   Simcox, Kelly ^b   Miller, Barry ^b   Gebauer, Alexander ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; OTAMIXABAN; TIROFIBAN; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; LETTER; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; VOLUNTEER;

EID: 16844382064     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616783     Document Type: Letter

References (11)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40: 1366-74.
2. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
3. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
5. Chu V, Brown K, Colussi D, et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res 2001; 103: 309-24.
6. Rebello SS, Bentley RG, Morgan SR, et al. Anti-thrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol. 2001; 133: 1190-8.
7. Paccaly AJ, Ozoux M, Frick A, et al. Pharmacokinetic/pharmacodynamic relationships for factor-Xa inhibitor XRP0673 in early drug development. AAPS PharmSci 2002; 4: (Abstract W5241).
8. Dyke CK, Becker RC, et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002; 105: 2382-8.
9. Alexander JH, Dyke CK, Yang H, et al. The XaNA-DU-PCI PILOT Investigators. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004; 2: 234-41.
10. Umemura K, Kondo K, Ikeda Y, et al. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotem IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997; 78: 1381-4.
11. Cohen M, Théroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273-81.